PEOPLE - Changes at Cygnus in the US:
This article was originally published in Clinica
Cygnus in the US has announced that Gregory Lawless has resigned as president, CEO and director to pursue other interests. He is succeeded by John Hodgman, who was previously president of the group's Cygnus Diagnostics subsidiary. In addition, Andre Marion, a Cygnus director, has been elected vice-chairman. The company is developing non-invasive glucose monitoring and drug delivery systems. A distribution agreement with Becton Dickinson for the glucose monitoring system, GlucoWatch, was ended in March.
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.